Pregabalin Capsule
Product Images NDC 67877-465

22 FDA label images from Ascend Laboratories, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 67877-465). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin-equation (Pregabalin Equation)

Pregabalin-equation (Pregabalin Equation)
A mathematical formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, with adjustment for female patients by multiplying by 0.85. The formula is presented as an equation with variables and constants.*
FDA Label Image

Pregabalin Structure (Pregabalin Srtuc 1)

Pregabalin Structure (Pregabalin Srtuc 1)
Chemical structure of pregabalin displaying its molecular framework, including the amino and carboxyl functional groups.*
FDA Label Image

Study Dpn 1 (Pregabalin Image 1)

Study Dpn 1 (Pregabalin Image 1)
A line graph depicting the percent of patients improved relative to percent improvement in pain from baseline. The graph compares Pregabalin at different dosages (25 mg, 100 mg, and 200 mg, each taken three times a day) and placebo, showing varying levels of patient improvement across pain reduction percentages.*
FDA Label Image

Study Dpn 2 (Pregabalin Image 2)

Study Dpn 2 (Pregabalin Image 2)
A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares two groups: one treated with Pregabalin 100 mg three times a day and a placebo group, illustrating efficacy differences in pain improvement between the treatments.*
FDA Label Image

Study Phn 1 (Pregabalin Image 3)

Study Phn 1 (Pregabalin Image 3)
A line graph showing percent of patients improved plotted against percent improvement in pain from baseline, comparing Pregabalin capsules at dosages of 75 mg, 150 mg, and 300 mg taken twice a day versus placebo. The graph illustrates trends of increasing patient improvement with higher dosages of Pregabalin.*
FDA Label Image

Study Phn 2 (Pregabalin Image 4)

Study Phn 2 (Pregabalin Image 4)
A line graph comparing the percent of patients improved against percent improvement in pain from baseline for Pregabalin 100 mg and 200 mg taken three times a day versus placebo. The graph shows three lines representing the treatment groups, illustrating the effectiveness at varying levels of pain improvement.*
FDA Label Image

Study Phn 3 (Pregabalin Image 5)

Study Phn 3 (Pregabalin Image 5)
A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. It includes three lines representing Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and a placebo group, showing the trends of pain improvement across these treatment groups.*
FDA Label Image

Pregabalin-figure-6 (Pregabalin Figure 6)

Pregabalin-figure-6 (Pregabalin Figure 6)
A bar chart comparing responder rates (%) across different dosages of pregabalin in two studies (E1 and E3). The x-axis shows placebo and various pregabalin doses (50 mg/day to 600 mg/day), with administration frequencies (BID or TID) noted. The y-axis represents responder rates from 0% to 60%. Higher doses generally show increased responder rates, with statistical significance indicated versus placebo.*
FDA Label Image

Pregabalin-figure-7 (Pregabalin Figure 7)

Pregabalin-figure-7 (Pregabalin Figure 7)
A line graph depicting seizure reduction as the median percentage change from baseline versus dose in mg/day. The graph shows data from multiple studies (E1 BID, E2 TID, E3 BID, E3 TID) with dose ranging from 0 (placebo) to about 450 mg/day. Significant p-values are annotated at various dose points, illustrating the seizure reduction trends associated with increasing doses.*
FDA Label Image

Pregabalin-fig-a (Pregabalin Fig A)

Pregabalin-fig-a (Pregabalin Fig A)
A bar graph showing responder rates (%) on the vertical axis for three groups: Placebo, 2.5 mg/kg/day, and 10 mg/kg/day. The responder rate increases across groups, with the placebo group at 22.6%, 2.5 mg/kg/day at 29.1%, and 10 mg/kg/day at 40.6%. The sample sizes (N) are 93, 103, and 96 respectively.*
FDA Label Image

Fibromyalgia Study F1 (Pregabalin Image 8)

Fibromyalgia Study F1 (Pregabalin Image 8)
A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares three Pregabalin daily doses (600 mg, 450 mg, 300 mg) and a placebo, with each dose represented by separate lines tracking patient response across the improvement spectrum.*
FDA Label Image

Fibromyalgia Study F2 (Pregabalin Image 9)

Fibromyalgia Study F2 (Pregabalin Image 9)
A line chart comparing the estimated percentage of subjects without LTR over 180 days for Pregabalin versus Placebo. The x-axis represents Days, and the y-axis shows the estimated percentage of subjects without LTR from 0% to 100%. Two lines are plotted: one solid line for Pregabalin and one dashed line for Placebo, demonstrating differences in survival without LTR over time.*
FDA Label Image

Study Sci 1 (Pregabalin Image 10)

Study Sci 1 (Pregabalin Image 10)
A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to week 12, contrasting Pregabalin and Placebo groups. The x-axis represents percent improvement from baseline to week 12, and the y-axis shows the percent of subjects improved. Pregabalin's line demonstrates higher improvement percentages compared to Placebo throughout the range.*
FDA Label Image

Pain Intensity-study Sci 2 (Pregabalin Image 11)

Pain Intensity-study Sci 2 (Pregabalin Image 11)
A line graph showing the percentage of subjects improved over time from baseline to week 16 based on BOCF (Baseline Observation Carried Forward) analysis. Two lines compare Pregabalin and placebo, depicting a higher percentage of improvement with Pregabalin across the timeline.*
FDA Label Image

Prega-25mg-90s-a (Prega 25mg 90s A)

Prega-25mg-90s-a (Prega 25mg 90s A)
Pregabalin Capsules 25 mg oral capsules label by Ascend Laboratories, LLC. The label states each hard gelatin capsule contains 25 mg pregabalin. It includes prescription-only designation and a 90-capsule count. Storage instructions, medication guide advisory, manufacturing by Alkem Laboratories (India), and distribution by Ascend Laboratories (NJ) are noted. The label also features a barcode and NDC 67877-462-90.*
FDA Label Image

Prega-50mg-500s-a (Prega 50mg 500s A)

Prega-50mg-500s-a (Prega 50mg 500s A)
Label for Pregabalin Capsules 50 mg by Ascend Laboratories, LLC. The label states the dosage form as capsules and includes a package count of 500 capsules. It provides storage instructions, manufacturing and distribution information, and a barcode. The label instructs to dispense the accompanying Medication Guide and is marked Rx Only.*
FDA Label Image

Pregabalin 75 mg 90 Counts (Pregabalin 75 90 1)

Pregabalin 75 mg 90 Counts (Pregabalin 75 90 1)
Pregabalin Capsules 75 mg oral capsules label, manufactured by Alkem Laboratories Ltd and distributed by Ascend Laboratories, LLC. The carton contains 90 capsules and includes storage instructions (store at 25°C with permitted excursions), dosage guidance, and a barcode. The label emphasizes dispensing the accompanying Medication Guide and is marked Rx Only.*
FDA Label Image

Prega-100mg-90s-a (Prega 100mg 90s A)

Prega-100mg-90s-a (Prega 100mg 90s A)
Label for Pregabalin Capsules 100 mg, an oral capsule product by Ascend Laboratories, LLC. The label indicates a package of 90 capsules with prescription use only. It includes storage instructions, manufacturing details by Alkem Laboratories Ltd., India, and advises dispensing the accompanying Medication Guide. The NDC is partially visible as 67877-465-90.*
FDA Label Image

Prega-150mg-90s-a (Prega 150mg 90s A)

Prega-150mg-90s-a (Prega 150mg 90s A)
Label for Pregabalin Capsules 150 mg, oral dosage form by Ascend Laboratories, LLC. The label indicates the product contains 150 mg pregabalin per hard gelatin capsule. It includes storage instructions, manufacturer details (Alkem Laboratories Ltd., India), distributor information, a barcode, and a reference to an accompanying medication guide. The package contains 90 capsules.*
FDA Label Image

Prega-200mg-500s-a (Prega 200mg 500s A)

Prega-200mg-500s-a (Prega 200mg 500s A)
Pregabalin Capsules 200 mg hard gelatin capsules label by Ascend Laboratories, LLC. The label includes dosage form, strength, NDC 67877-467-05, packaging count of 500 capsules, storage instructions, and manufacturer details from Alkem Laboratories Ltd., India. It also directs to the medication guide and includes barcodes.*
FDA Label Image

Prega-225mg-90s-a (Prega 225mg 90s A)

Prega-225mg-90s-a (Prega 225mg 90s A)
Label for Pregabalin Capsules 225 mg by Ascend Laboratories, LLC. The label indicates oral capsule dosage form, contains 90 capsules, and includes storage instructions and manufacturer information from Alkem Laboratories, Ltd. The NDC number 67877-468-90 is displayed along with a barcode and a note about UV varnish area.*
FDA Label Image

Prega-300mg-90s-a (Prega 300mg 90s A)

Prega-300mg-90s-a (Prega 300mg 90s A)
Pregabalin Capsules 300 mg oral capsule label from Ascend Laboratories, LLC. The label indicates each hard gelatin capsule contains 300 mg of pregabalin and includes storage instructions, dispensing guideline, and a note to provide the Medication Guide to each patient. The package contains 90 capsules and displays a National Drug Code (NDC) number along with manufacturer and distributor information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.